...
首页> 外文期刊>Advances in Orthopedics >Long-Term Effectiveness of Polymerized-Type I Collagen Intra-Articular Injections in Patients with Symptomatic Knee Osteoarthritis: Clinical and Radiographic Evaluation in a Cohort Study
【24h】

Long-Term Effectiveness of Polymerized-Type I Collagen Intra-Articular Injections in Patients with Symptomatic Knee Osteoarthritis: Clinical and Radiographic Evaluation in a Cohort Study

机译:患有症状膝关系骨关节炎患者的聚合I型I型胶原蛋白的长期有效性:在队列研究中的临床和放射线摄影

获取原文
           

摘要

Objective. Polymerized-type I collagen (polymerized-collagen) is a downregulator of inflammation and a tissue regenerator. The aim was to evaluate the effect of intra-articular injections (IAIs) of polymerized-collagen among patients with symptomatic knee osteoarthritis (OA) in delaying or preventing joint replacement surgery. Patients and Methods. This was a cohort study of 309 patients with knee OA. Patients with mild-to-moderate disease were treated weekly with IAIs of 2?mL of polymerized-collagen for six weeks (n?=?309). Follow-up was for 6–60 months. The primary endpoints included the following determinations: (1) therapeutic effect; (2) survival from total knee replacement surgery (TKR); (3) Western Ontario and McMaster University Osteoarthritis Index (WOMAC) and pain (visual analogue scale, VAS). Clinical improvement was defined as a decrease in pain exceeding 20?mm on the VAS and the achievement of at least 20% improvement from baseline with respect to the WOMAC score. Radiographic analysis was performed at baseline and 60 months. The joint space width in the medial, lateral, and patellofemoral compartments was calculated. Results. Patients who received IAIs of polymerized-collagen had a statistically significant improvement in the primary criteria (p0.05). Kaplan–Meier survival analysis of the therapeutic effect demonstrated 98.8% survival at 60 months with TKR as the endpoint. There was no significant reduction in joint space in any compartment based on the analyzed radiographs. No serious adverse events were recorded. Conclusion. Polymerized-collagen increased the time to TKR by at least 60 months, modifying the disease course, improving functional disability, and decreasing pain.
机译:客观的。聚合型I胶原(聚合胶原)是炎症的下调剂和组织再生器。目的是评估关节内注射(IAI)的患者患者患者患者患者患者的患者患者 - 膝关节骨关节炎(OA)延迟或预防关节置换手术。患者和方法。这是309例膝关节OA患者的队列研究。患有温和至中等疾病的患者每周处理2?ml聚合 - 胶原蛋白的IAIs六周(n?= 309)。随访时间为6-60个月。主要终点包括以下确定:(1)治疗效果; (2)从全膝关节替代手术中存活(TKR); (3)西部安大略省和麦克马斯特大学骨关节炎指数(Womac)和疼痛(视觉模拟量表,VAS)。临床改善被定义为VAS上超过20毫米的疼痛减少,并且从基线与WOMAC评分的实现至少20%的改善。射线照相分析在基线和60个月内进行。计算内侧,横向和髌户间隔内的关节空间宽度。结果。接受聚合胶原蛋白的IAI的患者在初级标准中具有统计学显着的改善(P <0.05)。 KAPLAN-MEIER治疗效果的存活分析在60个月内存在98.8%,TKR作为终点。基于分析的射线照相的任何隔室中的联合空间没有显着减少。没有记录严重的不良事件。结论。聚合 - 胶原蛋白将时间增加到tkr至少60个月,修饰疾病过程,改善功能性残疾,并降低疼痛。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号